Table 2.
Baseline Characteristics of Chronic HCV Patients Categorized by Race
| Characteristic* | All | White | Black | Latino | Asian/PI | Other | p value† |
|---|---|---|---|---|---|---|---|
| N = 3673 | N = 1400 | N = 1584 | N = 426 | N = 190 | N = 51 | ||
| Birth year (n, %) | |||||||
| 1960–1965 | 1077 (29.3) | 471 (33.6) | 364 (23.0) | 162 (38.0) | 54 (28.4) | 19 (37.3) | < 0.001 |
| 1955–1959 | 1107 (30.1) | 434 (31.0) | 477 (30.1) | 120 (28.2) | 58 (30.5) | 9 (17.7) | |
| 1950–1954 | 1002 (27.3) | 333 (23.8) | 507 (32.0) | 100 (23.5) | 45 (23.7) | 13 (25.5) | |
| 1945–1949 | 487 (13.3) | 162 (11.6) | 236 (14.9) | 44 (10.3) | 33 (17.4) | 10 (19.6) | |
| Gender (n, %) | |||||||
| Male | 2685 (73.1) | 1035 (73.9) | 1158 (73.1) | 339 (79.6) | 96 (50.5) | 37 (72.6) | < 0.001 |
| Female | 988 (26.9) | 365 (26.1) | 426 (26.9) | 87 (20.4) | 94 (49.5) | 14 (27.5) | |
| English as preferred language (n, %) | |||||||
| Yes | 3049 (83.0) | 1210 (86.4) | 1382 (87.3) | 305 (71.6) | 105 (55.3) | 39 (76.5) | < 0.001 |
| No | 185 (5.0) | 25 (1.8) | 9 (0.6) | 76 (17.8) | 70 (36.8) | 5 (9.8) | |
| Missing | 439 (12.0) | 165 (11.8) | 193 (12.2) | 45 (10.6) | 15 (7.9) | 7 (13.7) | |
| CKD (n, %) | |||||||
| Yes | 749 (20.4) | 199 (14.2) | 446 (28.2) | 63 (14.8) | 29 (15.3) | 7 (13.7) | < 0.001 |
| No | 2912 (79.3) | 1196 (85.4) | 1132 (71.5) | 363 (85.2) | 160 (84.2) | 44 (86.3) | |
| Missing | 12 (0.3) | 5 (0.4) | 6 (0.4) | 0 (0.0) | 1 (0.5) | 0 (0.0) | |
| HBV co-infection (n, %) | |||||||
| Yes | 53 (1.4) | 15 (1.1) | 22 (1.4) | 3 (0.7) | 11 (5.8) | 1 (2.0) | < 0.001 |
| No | 3386 (92.2) | 1276 (91.1) | 1475 (93.1) | 401 (94.1) | 168 (88.4) | 47 (92.2) | |
| Missing | 234 (6.4) | 109 (7.8) | 87 (5.5) | 22 (5.2) | 11 (5.8) | 3 (5.9) | |
| HIV co-infection (n, %) | |||||||
| Yes | 590 (16.1) | 248 (17.7) | 266 (16.8) | 48 (11.3) | 15 (7.9) | 9 (17.7) | 0.001 |
| No | 2903 (79.0) | 1071 (76.5) | 1265 (79.9) | 360 (84.5) | 154 (81.1) | 36 (70.6) | |
| Missing | 180 (4.9) | 81 (5.8) | 53 (3.4) | 18 (4.2) | 21 (11.1) | 6 (11.8) | |
| HCV genotype (n, %) | |||||||
| 1 | 1891 (51.5) | 622 (44.4) | 918 (58.0) | 226 (53.1) | 95 (50.0) | 16 (31.4) | < 0.001 |
| 2 | 200 (5.5) | 101 (7.2) | 41 (2.6) | 33 (7.8) | 20 (10.5) | 4 (7.8) | |
| 3 | 241 (6.6) | 145 (10.4) | 30 (1.9) | 48 (11.3) | 11 (5.8) | 6 (11.8) | |
| 4 | 29 (0.7) | 8 (0.6) | 17 (1.1) | 1 (0.2) | 2 (1.0) | 1 (2.0) | |
| 6 | 11 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 10 (5.3) | 1 (2.0) | |
| Mixed | 3 (0.1) | 2 (0.1) | 1 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Missing | 1298 (35.3) | 522 (37.3) | 577 (36.4) | 118 (27.7) | 52 (27.4) | 23 (45.1) | |
| Log10 HCVRNA (median, IQR) (IU/mL) | 6.06 (5.48–6.46) | 6.03 (5.40–6.46) | 6.09 (5.54–6.48) | 5.91 (5.32–6.38) | 6.13 (5.59–6.54) | 5.86 (5.07–6.30) | < 0.001 |
| ALT (median, IQR) (U/L) | 38 (24–63) | 38 (24–66) | 37 (25–57) | 42 (25–76) | 38 (21–69) | 31 (19–80) | 0.001 |
| Low platelets (n, %) (< 150 × 103/uL) | |||||||
| Yes | 732 (19.9) | 302 (21.6) | 239 (15.1) | 129 (30.3) | 41 (21.6) | 13 (25.5) | < 0.001 |
| No | 2926 (79.7) | 1094 (78.1) | 1338 (84.5) | 295 (69.3) | 148 (77.9) | 37 (72.6) | |
| Missing | 15 (0.4) | 4 (0.3) | 7 (0.4) | 2 (0.5) | 1 (0.5) | 1 (2.0) | |
| FIB-4 score | |||||||
| < 1.45 | 1109 (30.2) | 446 (31.9) | 486 (30.7) | 109 (25.6) | 47 (24.7) | 14 (27.5) | < 0.001 |
| 1.45–3.25 | 1641 (44.7) | 595 (42.5) | 764 (48.2) | 165 (38.7) | 95 (50.0) | 18 (35.3) | |
| > 3.25 | 860 (23.4) | 332 (23.7) | 315 (19.9) | 139 (32.6) | 47 (24.7) | 16 (31.4) | |
| Missing | 63 (1.7) | 27 (1.9) | 19 (1.2) | 13 (3.1) | 1 (0.5) | 3 (5.9) | |
*Missing data: 22 for race, 4 for HCVRNA, 8 for ALT. †p value considered statistically significant if < 0.05. ALT, alanine aminotransferase. CKD, chronic kidney disease, defined as eGFR ≤ 60 mL/min/1.73 m2. FIB-4, fibrosis-4 score. HBV co-infection, hepatitis B virus, defined as hepatitis B surface antigen positive. HCV, hepatitis C virus. HIV co-infection, human immunodeficiency virus, defined as the presence of HIV antibody. PI, Pacific Islander